查詢結果分析
相關文獻
- 癌症免疫治療:癌症治療新紀元
- Immunotherapy in Prostate Cancer: Past, Current, and Future
- 臺灣地區A型肝炎流行之演變與疫苗的成效
- 畜用免疫去勢方法的研發
- Characterization and Morphologic Analysis of Bovine Serum Albumin-Loaded Poly (S.C.-Lactide-Co-Glycolide) Microspheres
- Vaccine Storage Practices in Primary Care Physicians' Offices in Taiwan
- Immunogenicity and Reactogenicity of Two Recombinant Hepatitis B Vaccines in Healthy Adolescents on Two-dose Schedule
- Comparison of Immunogenicity of Simultaneous and Nonsimultaneous Vaccination with MMR and JE Vaccine Among 15-month-old Children
- Effect of Local Massage on Vaccination: DTP and DTPa
- 水痘感染與水痘疫苗之預防接種
頁籤選單縮合
題名 | 癌症免疫治療:癌症治療新紀元=Cancer Immunotherapy: A New Era in Cancer Treatment |
---|---|
作者 | 鄭吉元; 蔡慈貞; 張文震; | 書刊名 | 藥學雜誌 |
卷期 | 33:4=133 2017.12[民106.12] |
頁次 | 頁35-39 |
分類號 | 414.82 |
關鍵詞 | 癌症免疫治療; 免疫檢查點抑制劑; 疫苗; 免疫細胞療法; Cancer immunotherapy; Immune checkpoint inhibitor; |
語文 | 中文(Chinese) |
中文摘要 | 不同於傳統的化療和標靶藥品是針對腫瘤,癌症免疫治療是使用自身的免疫系 統去對抗癌症,主要對象是治療病人而不是腫瘤。現今癌症免疫治療可分為三個大 方向:免疫檢查點抑制劑、疫苗、免疫細胞療法。免疫檢查點抑制劑在臺灣已上市 ipilimumab、nivolumab、pembrolizumab,其中 ipilimumab 是屬於 CTLA-4抑制劑,而 後兩者為 PD-1抑制劑。治療性癌症疫苗可分為完整腫瘤細胞疫苗、腫瘤抗原疫苗、病 毒為基礎的疫苗、樹突細胞為基礎的疫苗。免疫細胞療法中最令人期待的是 CAR-T。 合併治療是癌症免疫治療的未來主流,例如:併用不同機轉的免疫檢查點抑制劑、免 疫治療合併化療或放射線、疫苗併用免疫檢查點抑制劑等。期待在未來數年能夠將癌 症免疫治療靈活運用,讓更多患者能夠受惠以及達到治癒癌症的終極目標。 |
英文摘要 | Unlike conventional chemotherapy and targeted therapy for cancer, cancer immunotherapy is to harness the power of our own immune system to fight cancer rather than to combat the tumor directly. Today’s cancer immunotherapy can be divided into three major directions: immune checkpoint inhibitors, vaccines, and adoptive cell therapies. Three immune checkpoint inhibitors had been approved in Taiwan, namely, ipilimumab, nivolumab, and pembrolizumab which ipilimumab belongs to the CTLA-4 inhibitor and the latter two are PD-1 inhibitors. Therapeutic cancer vaccines include whole tumor cell vaccines, tumor antigen vaccines, virus-based vaccines, and dendritic cell-based vaccines. Among adoptive cell therapies, CAR-T is the most intriguing. The future of the mainstream cancer immunotherapy is combination therapy, for example, combination cancer immunotherapies with different mechanisms, immunotherapies plus chemotherapy and radiation, and vaccines plus immune checkpoint inhibitors. More flexible application of cancer immunotherapy needs to be done to bring the benefits of immunotherapy to more types of cancer and more patients, and achieve the ultimate goal of cancer cure. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。